Antihyperthyroidism-associated agranulocytosis
Conditions
Interventions
Anti-hyperthyroidism drug granule deficiency group:None
Anti-hyperthyroidism drug tolerance group:None
Sponsors
Fujian Medical University Affiliated Union Hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. 18 years < age< 75 years; 2. Subject is diagnosed with GD based on clinical and biochemical hyperthyroidism, thyroidoid proptosis or diffuse goiter, and significant titers of autoantibodies; 3. All patients received ATDS, including MMI or PTU; 4. Criteria for agranulocytosis caused by ATD: First, before giving ATD to the patient, confirm that his granulocyte count is greater than or equal to 2.0×10^9/L; Second, the granulocyte count was lower than 0.5×10^9/L after ATD treatment, and the granulocytopenia returned to normal after stopping ATD treatment; 5. Criteria for ATD tolerance: because 80% of ATD-induced agranulocytosis occurred in the first 3 months, the control group of anti-hyperthyroidism drug tolerance consisted of patients with hyperthyroidism who had received ATDS treatment for at least 3 months and had not yet caused agranulocytosis; 6. Informed consent of the patient.
Exclusion criteria
Exclusion criteria: 1. Pregnant or lactating women; 2. Have a serious mental illness; 3. Anti-cancer chemotherapy within 1 month of the onset of agranulocytosis; 4. Radiation therapy within the previous month; 5. Bone marrow transplant at any time; 6. Persistent infection with Epstein-Barr virus, hepatitis A virus, HIV, cytomegalovirus or parvovirus B19; 7. Persistent sepsis; 8. Miliary tuberculosis; 9. Presence of chronic neutropenia (congenital cyclic or idiopathic); 10. Immunosuppressive therapy with cytotoxic drugs; 11. The phenomenon of malignant invasion of bone marrow; 12. Blood diseases (such as myelodysplasia, aplastic anemia, pancytopenia and other blood diseases); 13. Other autoimmune diseases: such as systemic lupus erythematosus.
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| T cell proliferation;CD107a assay; | — |
Primary
| Measure | Time frame |
|---|---|
| Disease immune cell picture;t-distributed stochastic neighbolembedding;Uniform Manifold Approximationand Projection;Gene violin map;Disease key gene;Clustering heat map; | — |
Countries
China
Contacts
Public ContactMa Li
Fujian Medical University Affiliated Union Hospital
Outcome results
None listed